liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Long-term benefit from adjuvant tamoxifen therapy for ER+HER2-breast cancer by PR positivity
Gothenburg Univ, Sweden.
Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden.
Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden.
Karolinska Inst, Sweden.
Show others and affiliations
2026 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 159, no 2, p. 450-459Article in journal (Refereed) Published
Abstract [en]

We aimed to evaluate the long-term tamoxifen benefit by progesterone receptor (PR) levels in postmenopausal lymph node-negative breast cancer patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2-negative (HER2) tumors in the STO-3 randomized trial. This is a secondary analysis of the STO-3 trial including 559 postmenopausal breast cancer patients by PR levels. Patients were randomly assigned to at least 2 years of adjuvant tamoxifen therapy (40 mg once daily) versus no endocrine therapy in the Stockholm (STO)-3 trial. Twenty-five-year distant recurrence-free interval (DRFI) was assessed by Kaplan-Meier, multivariable Cox proportional hazard regression, and multivariable time-varying analyses. Univariable Kaplan-Meier analysis showed a significant long-term tamoxifen benefit for PR-positive disease using a threshold of 10% or greater (DRFI, tamoxifen treated 85% vs. control 68%; p < .0001). Similarly, patients with high PR gene expressing tumors had a significant long-term tamoxifen therapy benefit (DRFI, tamoxifen treated 84% vs. control 66%; log-rank p < .001). In contrast, we report no significant therapy benefit for patients with PR-negative disease (DRFI, tamoxifen treated 79% vs. control 70%; log-rank p = .14) or low PR gene expression (DRFI, tamoxifen treated 82% vs. control 74%; log-rank p = .17). Multivariable Cox proportional hazard regression modelling confirmed the univariable findings for PR-positive disease (HR = 0.37; 95% CI [0.23-0.61]). Time-varying analysis revealed a treatment benefit for PR-positive disease up to 25 years (HR = 0.35; 95% CI [0.16-0.79]), but not for patients with PR-negative tumors. PR-positivity as determined by immunohistochemistry predicted long-term benefit from adjuvant tamoxifen in lymph node-negative postmenopausal breast cancer patients with ER+/HER2- tumors.

Place, publisher, year, edition, pages
WILEY , 2026. Vol. 159, no 2, p. 450-459
Keywords [en]
breast cancer; estrogen receptor; long-term endocrine therapy benefit; progesterone receptor; tamoxifen therapy
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-221931DOI: 10.1002/ijc.70409ISI: 001707377700001PubMedID: 41787605Scopus ID: 2-s2.0-105032151639OAI: oai:DiVA.org:liu-221931DiVA, id: diva2:2046617
Note

Funding Agencies|Swedish Breast Cancer Foundation; Stiftelsen Gsta Miltons Donationsfond; Vetenskapsrdet [2020-02466, 2023-03009]; Lions Cancerfond Vst [2023:8]; Cancerfreningen i Stockholm [181093, 201212, 221233]; Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer [2022:414]; Cancerfonden [220552SIA, 222081, 222216]

Available from: 2026-03-17 Created: 2026-03-17 Last updated: 2026-05-29

Open Access in DiVA

fulltext(909 kB)38 downloads
File information
File name FULLTEXT01.pdfFile size 909 kBChecksum SHA-512
9ba442e73bb8a9c161c8ba71c79d6624951aebb02a5cfc2b67fe49504d24a679ea19ac2b5136a221041a3c54810a9ce9319dd3397b1565bc109f38ee1b92b21b
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Perez-Tenorio, GizehFohlin, HelenaStål, Olle
By organisation
Division of Surgery, Orthopedics and OncologyFaculty of Medicine and Health SciencesDepartment of OncologyRegional Cancer Center
In the same journal
International Journal of Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 38 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 66 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf